INNOCARE (09969) Reports Interim Results with Adjusted Loss of RMB 15.504 Million, Narrowing 93.62% Year-on-Year

Stock News

Aug 19

INNOCARE (09969) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 731 million, representing a 74.26% year-on-year increase. The adjusted loss for the period was RMB 15.504 million, a 93.62% reduction compared to the same period last year. Loss attributable to shareholders was RMB 30.091 million, down 88.51% year-on-year, with a loss per share of RMB 0.02.

According to the announcement, the revenue increase was primarily driven by strong sales growth of Orelabrutinib and licensing income from Prolium. Orelabrutinib revenue increased 52.8% from RMB 417 million for the six months ended June 30, 2024, to RMB 637 million for the six months ended June 30, 2025, due to expanded coverage and an increase in treated patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1162851948"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162851948\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162851948?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162851948","market":"other","top_or_hot":-1,"title":"INNOCARE (09969) Reports Interim Results with Adjusted Loss of RMB 15.504 Million, Narrowing 93.62% Year-on-Year","media":"Stock News","content":"<p>INNOCARE (09969) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 731 million, representing a 74.26% year-on-year increase. The adjusted loss for the period was RMB 15.504 million, a 93.62% reduction compared to the same period last year. Loss attributable to shareholders was RMB 30.091 million, down 88.51% year-on-year, with a loss per share of RMB 0.02.</p>\n<p>According to the announcement, the revenue increase was primarily driven by strong sales growth of Orelabrutinib and licensing income from Prolium. Orelabrutinib revenue increased 52.8% from RMB 417 million for the six months ended June 30, 2024, to RMB 637 million for the six months ended June 30, 2025, due to expanded coverage and an increase in treated patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOCARE (09969) Reports Interim Results with Adjusted Loss of RMB 15.504 Million, Narrowing 93.62% Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOCARE (09969) Reports Interim Results with Adjusted Loss of RMB 15.504 Million, Narrowing 93.62% Year-on-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-19 18:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOCARE (09969) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 731 million, representing a 74.26% year-on-year increase. The adjusted loss for the period was RMB 15.504 million, a 93.62% reduction compared to the same period last year. Loss attributable to shareholders was RMB 30.091 million, down 88.51% year-on-year, with a loss per share of RMB 0.02.</p>\n<p>According to the announcement, the revenue increase was primarily driven by strong sales growth of Orelabrutinib and licensing income from Prolium. Orelabrutinib revenue increased 52.8% from RMB 417 million for the six months ended June 30, 2024, to RMB 637 million for the six months ended June 30, 2025, due to expanded coverage and an increase in treated patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1162851948","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162851948","pubTimestamp":1755600053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOCARE (09969) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 731 million, representing a 74.26% year-on-year increase. The adjusted loss...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK1574":"生物医药B类股","09969":"诺诚健华","BK0239":"医药制造","BK1161":"生物科技"},"translate_title":"诺诚健华(09969)公布中期业绩经调整亏损1550.4万元同比收窄93.62%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":1},"content_text":"INNOCARE (09969) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 731 million, representing a 74.26% year-on-year increase. The adjusted loss for the period was RMB 15.504 million, a 93.62% reduction compared to the same period last year. Loss attributable to shareholders was RMB 30.091 million, down 88.51% year-on-year, with a loss per share of RMB 0.02.\nAccording to the announcement, the revenue increase was primarily driven by strong sales growth of Orelabrutinib and licensing income from Prolium. Orelabrutinib revenue increased 52.8% from RMB 417 million for the six months ended June 30, 2024, to RMB 637 million for the six months ended June 30, 2025, due to expanded coverage and an increase in treated patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}